Samsung’s newest glucose patent, published September 9, 2026, describes a wearable that cannot read blood sugar by itself. The method needs a reading from a separate glucose device first, then calibrates against it.
Key Takeaways
- Samsung’s European filing describes a wearable that calculates glucose only after a separate device supplies a reference reading.
- The patent family traces back to a priority date of December 11, 2023, with Korean and international publications following in June 2025.
- Samsung executive Jong-min Choi confirmed the same week that noninvasive continuous glucose monitoring remains an active research effort.
- The FDA has authorized no smartwatch or smart ring to measure or estimate blood glucose on its own.
- Galaxy Watch owners gain no new capability from this filing. The AGEs Index still reports no blood sugar value.
What We Know?
The application, published as EP4803002A1, covers a wearable electronic device with sensors, memory, a display, communications hardware, and a processor. Its glucose routine opens with a step most coverage of wearable glucose skips. The device identifies a time for the user to take a blood glucose reading on an external device.
A sensor on the wearable captures a biometric signal from the user at around that same moment. The wearable then pairs the externally measured glucose value with its own biometric signal to build calibration data. That calibration data is what lets the wearable translate later biometric signals into glucose values.
The sequence puts the accuracy problem where it has always sat. A known glucose number still has to come from a device that measures glucose, and the wearable’s job is to anchor its own signal to that number. Samsung filed the priority application on December 11, 2023, published a Korean application on June 18, 2025, and followed with an international PCT publication a day later.
Samsung’s research runs wider than the watch
Jong-min Choi, an executive vice president on Samsung’s Digital Health Team, addressed the underlying research at a health briefing held the same day the European application appeared. “We are pursuing a multifaceted approach that includes global technology exploration, in-house research, and collaboration with external startups (POC),” Choi said, adding that noninvasive blood glucose measurement is “an extremely challenging field” where the company keeps working on reliability.
Choi also pointed at hardware combinations. Wearing a Galaxy Ring alongside a Galaxy Watch improves sensor measurement accuracy, he said, and Samsung’s stated plan connects watches, rings, phones, and Buds into one personalized AI health setup. The company’s broader Samsung hardware and revenue picture gives that ecosystem push its commercial logic.
What We Don’t Know?
The filing settles far less than its headline suggests. Open questions that neither the patent nor the briefing answers:
- Which biometric signal the wearable actually measures, and how it correlates with glucose?
- How often a user would need to repeat the external reference measurement?
- What accuracy the calibrated estimate achieves against a laboratory or CGM benchmark?
- Whether any shipping Galaxy Watch will use the method, and whether the European application is granted at all?
A patent describes a method someone wanted to protect. It does not show that the method works well enough to sell, and Samsung has announced no Galaxy Watch that measures blood glucose independently.
What’s Next?
Starting from an externally measured number is an honest engineering position. Optical and electrical signals at the wrist drift with skin tone, temperature, perfusion, and fit, so the hard part was never capturing a signal. It was deciding what that signal means for one particular person on one particular day. Borrowing a trusted number from a fingerstick or a CGM, then mapping the wrist signal onto it, is the same trick medical devices have used for decades. It also caps the upside, because a device that needs a reference reading has not replaced the reference device.
What comes next is examination. European applications typically take years to reach grant, and the claims usually narrow on the way. Watch for three things: whether Samsung’s next health briefing puts a number on calibration accuracy, whether the wearables market’s accuracy standards tighten around health claims, and whether any regulator clears a wrist-worn glucose feature at all. Until one does, a watch that estimates blood sugar stays a research program with a filing number attached.
